Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics股價上漲，公司宣佈在加州大學舊金山分校進行的RIDGE-1第10億期臨床試驗中爲首位患者注射了TN-401基因療法。
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics宣佈在加州大學舊金山分校進行的 RIDGE-1 第10期臨床試驗中向首位患者注射 TN-401 基因療法，此後，該公司股價走高。
資訊熱榜
更新時間